Skip to Content

Join the 'Non-Hodgkin's Lymphoma' group to help and get support from people like you.

Non-Hodgkin's Lymphoma News

Related terms: Cancer, Non-Hodgkin's Lymphoma, Histiocytic Lymphoma, Lymphoblastic Lymphoma, Lymphocytic Lymphoma, Lymphoma, Histiocytic, Lymphoma, Lymphoblastic, Lymphoma, Lymphocytic, Lymphoma, Non-Hodgkin's

Genetically Modified Foods, Herbicides and Human Safety

Posted 12 days ago by Drugs.com

WEDNESDAY, Aug. 19, 2015 – Farm fields are becoming soaked with increasing amounts of suspected cancer-causing herbicides, thanks to the spread of genetically modified crops that are immune to these chemicals, two researchers contend. They make their argument in a Perspective piece in the Aug. 20 issue of the New England Journal of Medicine. Farmers' use of glyphosate – a weedkiller most commonly known as Roundup – has increased by a factor of more than 250 in the United States, climbing from 0.4 million kilograms in 1974 to 113 million kilograms in 2014, the researchers said. This increase is due to crops such as corn and soybeans that have been genetically altered to be "Roundup-Ready," so they can't be affected by these herbicides, said one of the researchers, Charles Benbrook. He is a research professor at the Washington State University Center for Sustaining Agriculture and ... Read more

Related support groups: Cancer, Poisoning, Non-Hodgkin's Lymphoma, Toxic Reactions Incl Drug and Substance Abuse

2 Drugs Show Promise Against Blood Cancers

Posted 30 May 2015 by Drugs.com

SATURDAY, May 30, 2015 – Two new drugs have shown promise in slowing the march of two incurable blood cancers, researchers report. One drug, ibrutinib, appears to greatly improve standard treatment for patients with recurring chronic-lymphocytic leukemia (CLL), the most common adult leukemia in Western countries. Ibrutinib (Imbruvica) reduced the risk of cancer progression or death by 80 percent when combined with a chemotherapy drug called bendamustine (Treanda) and a targeted therapy drug called rituximab (Rituxan), compared to the other two drugs being used on their own, the researchers found. "We found that if you add ibrutinib to the standard regimen, progression-free survival was significantly improved as a direct result of the ibrutinib," said lead author Dr. Asher Chanan-Khan, a professor of medicine at the Mayo Clinic in Jacksonville, Fla. Meanwhile, the second drug, ... Read more

Related support groups: Rituxan, Chronic Lymphocytic Leukemia (CLL), Rituximab, Non-Hodgkin's Lymphoma, Treanda, Bendamustine, Obinutuzumab, Gazyva

Fitness May Help Lower Odds for Non-Hodgkin's Lymphoma

Posted 1 May 2015 by Drugs.com

FRIDAY, May 1, 2015 – A lifetime of vigorous exercise may lower the risk of non-Hodgkin's lymphoma – a form of cancer that affects the lymph nodes, according to a new study. Activities that significantly increase breathing and heart rate appear to have the most benefit, the researchers said. "We know that being physically active reduces the risk of colon cancer and breast cancer, and also leads to a range of other physical and mental health benefits," study author Terry Boyle, a postdoctoral fellow at the University of British Columbia in Canada, said in a news release from the American Association for Cancer Research. "Our findings suggest that people who do vigorous physical activity may also have a lower risk for non-Hodgkin's lymphoma," Boyle added. While this study found an association between intense physical activity and a reduced risk of non-Hodgkin's lymphoma, it wasn't ... Read more

Related support groups: Non-Hodgkin's Lymphoma

FDA Expands Approved Use of Imbruvica for Waldenström’s Macroglobulinemia

Posted 29 Jan 2015 by Drugs.com

January 29, 2015 – The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) for patients with Waldenström’s macroglobulinemia (WM), a rare form of cancer that begins in the body’s immune system. The drug received a breakthrough therapy designation for this use. A type of non-Hodgkin lymphoma, WM usually gets worse slowly over time and causes abnormal blood cells, known as B lymphocytes (B-cells), to grow within the bone marrow, lymph nodes, liver, and spleen. In WM, abnormal B-cells also overproduce a protein known as immunoglobulin M or IgM (macroglobulin) that may lead to excess bleeding, problems with vision and with the nervous system. According to the National Cancer Institute, approximately 70,800 Americans were diagnosed and 18,990 died from non-Hodgkin lymphomas in 2014. Imbruvica works by blocking the enzyme that allows the abnormal B-ce ... Read more

Related support groups: Non-Hodgkin's Lymphoma, Imbruvica, Ibrutinib

Lymphoma Treatment May Harm, Halt Men's Sperm Production

Posted 26 Jul 2014 by Drugs.com

FRIDAY, July 25, 2014 (HealthDay – Treatment for lymphoma may lower men's fertility, new research indicates. Both Hodgkin lymphoma and non-Hodgkin lymphoma, which are cancers of the body's white blood cells, often affect young people who are still in their reproductive years. For men, treatment for these cancers can harm or halt sperm production. Although most men regain their fertility within two years of treatment, the researchers cautioned that men should be counseled about the possibility of this significant side effect before treatment begins. "While many men can look forward to their fertility returning after treatment is over, not all will be so fortunate," Dr. Rebecca Sokol, president of the American Society for Reproductive Medicine, said in a society news release. "It is imperative that prior to the initiation of therapy, counseling and sperm preservation be made available to ... Read more

Related support groups: Lymphoma, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma

FDA Approves Zydelig (idelalisib) for CLL and Lymphoma

Posted 23 Jul 2014 by Drugs.com

July 23, 2014 – The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers. Zydelig is being granted traditional approval to treat patients whose chronic lymphocytic leukemia (CLL) has returned (relapsed). Used in combination with Rituxan (rituximab), Zydelig is to be used in patients for whom Rituxan alone would be considered appropriate therapy due to other existing medical conditions (co-morbidities). Zydelig is the fifth new drug with breakthrough therapy designation to be approved by the FDA and the third drug with this designation approved to treat CLL. The FDA is also granting Zydelig accelerated approval to treat patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) and relapsed small lymphocytic lymphoma (SLL), another type of non-Hodgkin lymphoma. Zydelig is intended to be used in patients who ... Read more

Related support groups: Leukemia, Lymphoma, Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma, Follicular Lymphoma

Zydelig Approved for Three Types of Blood Cancer

Posted 23 Jul 2014 by Drugs.com

WEDNESDAY, July 23, 2014 – Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, including chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL) and small lymphocytic lymphoma (SLL), the FDA said Wednesday in a news release. The approval for the three forms of blood cancer covers instances when the cancer returns despite treatment with at least one other therapy, the agency said. The drug's label will include a boxed warning that the medication could cause liver toxicity, diarrhea, high blood sugar, elevated liver enzymes, high blood triglycerides [a blood fat] and inflammation of the colon (colitis). Other side effects noted during clinical testing included fever, fatigue, nausea, cough, pneumonia, abdominal pain, chills and rash. Zydelig is marketed by Gilead Sciences, based in Foster City, ... Read more

Related support groups: Lymphoma, Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma, Follicular Lymphoma

FDA Approves Beleodaq (belinostat) for Peripheral T-Cell Lymphoma

Posted 3 Jul 2014 by Drugs.com

July 3, 2014 – The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency’s accelerated approval program. PTCL comprises a diverse group of rare diseases in which lymph nodes become cancerous. In 2014, the National Cancer Institute estimates that 70,800 Americans will be diagnosed with NHL and 18,990 will die. PTCL represents about 10 to 15 percent of NHLs in North America. Beleodaq works by stopping enzymes that contribute to T-cells, a type of immune cell, becoming cancerous. It is intended for patients whose disease returned after treatment (relapsed) or did not respond to previous treatment (refractory). “This is the third drug that has been approved since 2009 for the treatment of peripheral T-c ... Read more

Related support groups: Lymphoma, Non-Hodgkin's Lymphoma, Peripheral T-cell Lymphoma

Beleodaq Approved for Aggressive non-Hodgkin Lymphoma

Posted 3 Jul 2014 by Drugs.com

THURSDAY, July 3, 2014 – Beleodaq (belinostat) has been approved by the U.S. Food and Drug Administration to treat peripheral T-Cell lymphoma (PTCL), a rare and aggressive form of non-Hodgkin lymphoma (cancer of the lymph nodes). Some 70,800 Americans will be diagnosed with non-Hodgkin lymphoma this year, of which up to 15 percent will be PTCL, according to U.S. National Cancer Institute estimates. Beleodaq is designed to inhibit immune cells called T-cells from becoming cancerous, the FDA explained Thursday in a news release. The drug is intended for people whose cancer has returned or who didn't respond to a prior therapy, the agency said. Beleodaq's safety and effectiveness were evaluated in clinical studies involving 129 people with PTCL. All were treated with the newly approved drug, and about 26 percent had their cancer disappear or shrink, the FDA said. The most common side ... Read more

Related support groups: Cancer, Lymphoma, Non-Hodgkin's Lymphoma, Peripheral T-cell Lymphoma

FDA Approves Imbruvica for Mantle Cell Lymphoma

Posted 13 Nov 2013 by Drugs.com

November 13, 2013 – The U.S. Food and Drug Administration today approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer. MCL is a rare form of non-Hodgkin lymphoma and represents about 6 percent of all non-Hodgkin lymphoma cases in the United States. By the time MCL is diagnosed, it usually has already spread to the lymph nodes, bone marrow and other organs. Imbruvica is intended for patients with MCL who have received at least one prior therapy. It works by inhibiting the enzyme needed by the cancer to multiply and spread. Imbruvica is the third drug approved to treat MCL. Velcade (2006) and Revlimid (2013) are also approved to treat the disease. “Imbruvica’s approval demonstrates the FDA’s commitment to making treatments available to patients with rare diseases,” said Richard Pazdur, M.D., director of the Office o ... Read more

Related support groups: Non-Hodgkin's Lymphoma

Early Stem Cell Transplant May Benefit Some Non-Hodgkin's Lymphoma Patients

Posted 31 Oct 2013 by Drugs.com

THURSDAY, Oct. 31 – Early stem cell transplants do not improve overall survival in high-risk patients with aggressive non-Hodgkin's lymphoma, but may be beneficial for a small group of patients with the very highest risk, according to a new study. Non-Hodgkin's lymphoma is cancer of the white blood cells (lymphocytes). Larger-than-normal lymph nodes and fever are common symptoms. Many patients with this type of cancer relapse after undergoing chemotherapy and require an autologous stem cell transplant. In that procedure, the patient's own stem cells are removed before they receive high-dose chemotherapy and/or radiation. After the chemotherapy, the patient's stem cells are returned to help replenish the body's supply of blood cells. This study of 397 patients in the United States and Canada looked at whether giving patients a stem cell transplant before they relapsed would improve ... Read more

Related support groups: Non-Hodgkin's Lymphoma

New Strategy Helps Young Lymphoma Patients Avoid Radiation Treatment

Posted 10 Apr 2013 by Drugs.com

WEDNESDAY, April 10 – A new treatment approach may mean that young people with a form of lymphoma can go without radiation therapy, sparing them side effects or raised cancer risks down the road. In a trial conducted by the U.S. National Cancer Institute, nearly all patients with a form of cancer known as primary mediastinal B-cell lymphoma who received chemotherapy, but did not undergo chest radiation, achieved a full remission. Standard treatment for this cancer typically includes radiation to the chest, the study authors pointed out, but this has been linked to significant harmful effects in the future, particularly for women. "These results are exciting and demonstrate that, using this approach, almost all patients appear to be cured and very few patients require radiation," study co-author Dr. Kieron Dunleavy, of the U.S. National Cancer Institute, said in an agency news release. ... Read more

Related support groups: Lymphoma, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma

Cancer Chemotherapy Tied to Slight Rise in Risk for Leukemia

Posted 14 Feb 2013 by Drugs.com

THURSDAY, Feb. 14 – Chemotherapy can be a lifesaver for thousands of cancer patients, but a new study suggests that it might slightly raise the odds for a type of leukemia later in life. Over the past 30 years, the risk for acute myeloid leukemia (AML) has increased for patients who underwent chemotherapy for certain forms of cancer, particularly non-Hodgkin lymphoma, the new study found. On the other hand, the researchers from the U.S. National Cancer Institute said other cancer survivors may have a reduced risk for AML due to a change in chemotherapy agents that occurred decades ago. One expert not connected to the study stressed that cancer patients need to put the findings into perspective. "It's important to realize that the risk of developing acute myeloid leukemia related to prior chemotherapy is small and increases with the number of chemotherapy treatments given over time," ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Lupron, Accutane, Medroxyprogesterone, Tamoxifen, Arimidex, Lupron Depot, Femara, Tretinoin, Gleevec, Fluorouracil, Rituxan, Zoladex, Votrient, Claravis, Tarceva, Avastin

'Rediscovered' Lymphoma Drug Helps Double Survival: Study

Posted 4 Jun 2012 by Drugs.com

SUNDAY, June 3 – A drug first developed in East Germany in the 1960s has re-emerged as a potent "new" weapon against certain types of non-Hodgkin lymphomas, researchers report. The drug, bendamustine, more than doubled disease progression-free survival when given along with another therapy, rituximab (Rituxan), compared to the drug cocktail that's long been used to fight indolent non-Hodgkin lymphomas. The bendamustine/rituximab combination also left patients with fewer side effects than the older treatment, the trial found. One expert, Dr. Joshua Brody, an assistant professor of hematology/oncology at Mount Sinai School of Medicine in New York City, called the findings "quite exciting." "Simultaneously increasing efficacy and decreasing toxicity is a rare win-win in oncology, and this has already prompted an enormous shift in the way we care for these patients," he said. The findings ... Read more

Related support groups: Rituxan, Rituximab, Non-Hodgkin's Lymphoma, Treanda, Bendamustine

Growing Up Near Livestock Tied to Blood Cancers

Posted 28 Jul 2011 by Drugs.com

THURSDAY, July 28 – Children raised on livestock farms are at significantly greater risk of developing blood cancers – such as leukemia, multiple myeloma and non-Hodgkin's lymphoma – later in life, a new study contends. The researchers pointed out that further studies will be needed before a definitive cause and effect can be established, but they suggested that exposure to particular viruses during childhood may modify the immune system response and result in a higher risk for blood cancer in adulthood. In conducting the study, published in the July 28 online edition of Occupational and Environmental Medicine, researchers compiled information from 114,000 death certificates for people between 35 and 85 years of age who died between 1998 and 2003 in New Zealand. The study found that over the five-year period, more than 3,000 deaths were attributed to blood cancers. Moreover, the ... Read more

Related support groups: Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Mantle Cell Lymphoma, Follicular Lymphoma, Cutaneous T-cell Lymphoma, Waldenström Macroglobulinemia, Peripheral T-cell Lymphoma, Burkitt Lymphoma, Lymphoma

Related Drug Support Groups

methotrexate, Rituxan, rituximab, Cytoxan, Treanda, cyclophosphamide, bendamustine, vincristine, Zevalin, view more... cytarabine, fludarabine, Zydelig, Cytosar, Cytosar-U, Cytoxan Lyophilized, Oncovin, Y-90 Zevalin, Trexall, Folotyn, Methotrexate LPF Sodium, Mozobil, Bexxar, Fludara, ibritumomab, bleomycin, plerixafor, tositumomab / iodine i 131 tositumomab, pralatrexate, teniposide, Oforta, carmustine, idelalisib, mitoxantrone, Blenoxane, Neosar, Vincasar PFS, Vumon, Folex PFS, Gliadel, Novantrone, BiCNU, Tarabine PFS, In-111 Zevalin